Document is current

Article History

Received: 16 December 2025

Accepted: 17 February 2026

First Online: 12 March 2026

Declarations

:

: This study was funded by Johnson & Johnson, who had a role in study design, analysis, interpretation, and manuscript development. Saiju Jacob has served as an international advisory board member or has been in the data monitoring committee for clinical trials for Johnson & Johnson, Alexion, Alnylam, Argenx, Immunovant, Merck, Novartis, Regeneron and UCB pharmaceuticals, is currently an expert panel member of Myasthenia Gravis consortium for Argenx pharmaceuticals and has received speaker fees from Argenx, Eisai, Terumo BCT and UCB pharmaceuticals. He is also a board member (trustee) of the UK myasthenia patient charity, Myaware. Mahmoud Hashim, Kavita Gandhi, Suzy Van Sanden, Rafal Slowik, Antoine C. El Khoury, Mi Jun Keng, and Sindhu Ramchandren are employees of Johnson & Johnson and may hold stock/stock options of Johnson & Johnson. Brian Hutton has previously received honoraria from Johnson & Johnson, EVERSANA, Maple Health Group, Stratenym, and Evidinno Outcomes Research Inc. for provision of methodologic advice related to the conduct of systematic reviews, meta-analyses, and indirect treatment comparisons. Christopher Drudge and Sumeet Singh are employees of EVERSANA. EVERSANA receives consultancy fees from pharmaceutical and device companies, including Johnson & Johnson. Nils Erik Gilhus has received consultative or speaker’s honoraria from Johnson & Johnson, UCB, Argenx, Alexion, Merck, Dianthus, Amgen, Roche, Grifols, Immunovant, Huma, Denka, Novartis, NMD Pharma, Lundbeck, and Takeda.

: This study used only data from previously conducted clinical trials, so institutional review board approval was not required.